At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 450 enrolled
Drug / intervention
Isavuconazole +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections
In Brief
A Phase 3 clinical trial evaluating Isavuconazole, Caspofungin, and 1 other intervention for Candidiasis, Invasive and 2 related conditions. Completed, enrolled 450 participants across 113 sites in 25 countries.
Detailed Summary
The purpose of the study is to compare the safety and efficacy of isavuconazole versus caspofungin followed by voriconazole in the treatment of candidemia and other invasive Candida infections.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCandidiasis, Invasive, Candidemia, Mycoses
CountriesArgentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Hungary, India, Israel, Italy, Lebanon, Malaysia, Mexico, New Zealand, Philippines, Russia, Singapore, South Africa, Spain, Switzerland, Thailand, United States
CollaboratorsBasilea Pharmaceutica
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 2006
Enrollment StartMar 2007
Primary CompletionMar 2015
TodayJul 2026
First PostedDec 19, 2006
Enrollment StartMar 8, 2007
Primary CompletionMar 3, 2015
TodayJul 2, 2026
Enrollment to primary: 8.0 yearsPosted 19.5 years ago
Interventions
Isavuconazoledrug
Administered by intravenous infusion.
Caspofungindrug
Administered by intravenous infusion.
Voriconazoledrug
Administered by intravenous infusion.